{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T23:02:34Z","timestamp":1770418954137,"version":"3.49.0"},"reference-count":36,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T00:00:00Z","timestamp":1587427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"Merck Sharp & Dohme Corp, a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2020,4,21]]},"abstract":"<jats:p>The RESTORE-IMI 1 phase 3 trial demonstrated the efficacy and safety of imipenem-cilastatin (IMI) combined with relebactam (REL) for treating imipenem-nonsusceptible infections. The objective of this analysis was to compare the outcomes among patients meeting eligibility requirements based on central laboratory susceptibility versus local laboratory susceptibility. Patients with serious infections caused by imipenem-nonsusceptible, colistin-susceptible, and imipenem-REL-susceptible pathogens were randomized 2:1 to IMI-REL plus placebo or colistin plus IMI for 5 to 21\u2009days.<\/jats:p>","DOI":"10.1128\/aac.02203-19","type":"journal-article","created":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T12:29:06Z","timestamp":1582201746000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":28,"title":["Comparison of Treatment Outcomes between Analysis Populations in the RESTORE-IMI 1 Phase 3 Trial of Imipenem-Cilastatin-Relebactam versus Colistin plus Imipenem-Cilastatin in Patients with Imipenem-Nonsusceptible Bacterial Infections"],"prefix":"10.1128","volume":"64","author":[{"given":"Keith S.","family":"Kaye","sequence":"first","affiliation":[{"name":"University of Michigan, Ann Arbor, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen W.","family":"Boucher","sequence":"additional","affiliation":[{"name":"Tufts Medical Center, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle L.","family":"Brown","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Aggrey","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ireen","family":"Khan","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hee-Koung","family":"Joeng","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert W.","family":"Tipping","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiejun","family":"Du","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Young","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan R.","family":"Butterton","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Paschke","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","unstructured":"Centers for Disease Control and Prevention. 2019. Antibiotic resistance threats in the United States 2019. https:\/\/www.cdc.gov\/drugresistance\/pdf\/threats-report\/2019-ar-threats-report-508.pdf. Accessed 16 January 2019."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx176"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy150"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-017-2383-z"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70190-7"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)30257-2"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2209"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02319-16"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ717"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir611"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1L001"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30099-9"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx438"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.5.1633-1641.2006"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12866-019-1522-7"},{"key":"e_1_3_2_17_2","volume-title":"Recarbrio\u2122 (imipenem, cilastatin, and relebactam) for injection, for intravenous use: US prescribing information","author":"Merck Sharp & Dohme Corp","year":"2019","unstructured":"Merck Sharp & Dohme Corp. 2019. Recarbrio\u2122 (imipenem, cilastatin, and relebactam) for injection, for intravenous use: US prescribing information. Merck Sharp & Dohme Corp, Whitehouse Station, NJ."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00830-15"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt178"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz354"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz530"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02209-16"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2018.05.017"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2018.07.012"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00633-16"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx139"},{"key":"e_1_3_2_27_2","volume-title":"Guidance for industry: microbiology data for systemic antibacterial drugs\u2014development, analysis, and presentation","author":"U.S. Food and Drug Administration","year":"2018","unstructured":"U.S. Food and Drug Administration. 2018. Guidance for industry: microbiology data for systemic antibacterial drugs\u2014development, analysis, and presentation. U.S. Department of Health and Human Services, U.S. Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Silver Spring, MD."},{"key":"e_1_3_2_28_2","unstructured":"European Medicines Agency. 2018. Guideline on the evaluation of medicinal products indicated for treatment of bacterial infections. https:\/\/www.ema.europa.eu\/en\/evaluation-medicinal-products-indicated-treatment-bacterial-infections. Accessed 27 January 2020."},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01934-17"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)30004-4"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-018-0214-1"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-019-0251-4"},{"key":"e_1_3_2_33_2","volume-title":"Guidance for industry: antibacterial therapies for patients with an unmet medical need for the treatment of serious bacterial diseases","author":"U.S. Food and Drug Administration","year":"2017","unstructured":"U.S. Food and Drug Administration. 2017. Guidance for industry: antibacterial therapies for patients with an unmet medical need for the treatment of serious bacterial diseases. U.S. Department of Health and Human Services, U.S. Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Silver Spring, MD."},{"key":"e_1_3_2_34_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2015","unstructured":"Clinical and Laboratory Standards Institute (CLSI). 2015. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 10th ed. CLSI document M07-A10. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"10"},{"key":"e_1_3_2_35_2","volume-title":"Performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2017","unstructured":"Clinical and Laboratory Standards Institute (CLSI). 2017. Performance standards for antimicrobial susceptibility testing, 27th ed. CLSI supplement M100. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"27"},{"key":"e_1_3_2_36_2","unstructured":"European Committee on Antimicrobial Susceptibility Testing. 2019. Breakpoint tables for interpretation of MICs and zone diameters version 9.0. http:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_9.0_Breakpoint_Tables.pdf. Accessed 16 January 2019."},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780040211"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02203-19","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02203-19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:45:36Z","timestamp":1645479936000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02203-19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,21]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,4,21]]}},"alternative-id":["10.1128\/AAC.02203-19"],"URL":"https:\/\/doi.org\/10.1128\/aac.02203-19","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,21]]},"assertion":[{"value":"2019-11-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02203-19"}}